Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bromocriptine and Pleuropulmonary Disease

Bromocriptine and Pleuropulmonary Disease Abstract Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically since 1969.1 This drug has been effective in the management of patients with hyperprolactinemia with or without a demonstrable prolactin-secreting adenoma, growth hormone-secreting pituitary adenomas, postpartum lactation, and Parkinson's disease.2 The drug also has been safely used in the management of pregnant women harboring prolactin-secreting pituitary tumors.3 In addition, the drug has been tried in some patients with luteal-phase insufficiency, idiopathic edema, premenstrual tension syndrome, and hepatic encephalopathy, although the data supporting the use of the drug in these latter conditions either are incomplete or require substantiation.1 During the 20 years of clinical experience, bromocriptine has been found to be remarkably free of major side effects.4 Patients commonly develop nausea, occasionally with abdominal cramps and vomiting, and postural hypotension at the time therapy is initiated. These side effects can References 1. Vance ML, Evans WS, Thorner MO: Bromocriptine . Ann Intern Med 1984;100:78-91.Crossref 2. Jordan RM, Kohler PO: Recent advances in diagnosis and treatment of pituitary tumors . Adv Intern Med 1987;32:299-324. 3. Melmed S, Braunstein GD, Chang J, et al: Prolactin and growth hormone-secreting pituitary tumors . Ann Intern Med 1986;105:238-253.Crossref 4. Weil C: The safety of bromocriptine in hyperprolactinemic female infertility: A literature review . Curr Med Res Opin 1986;10:172-195.Crossref 5. McElvaney NG, Wilcox PG, Churg AM, et al: Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease . Arch Intern Med 1988;148:2231-2236.Crossref 6. Wiggins J, Skinner C: Bromocriptine induced pleuropulmonary fibrosis . Thorax 1986;41:328-330.Crossref 7. Rinne UK: Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease . Lancet 1981;1:44.Crossref 8. Taal BG, Spierings EL, Hilvering C: Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine . Thorax 1983;38:396-398.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Bromocriptine and Pleuropulmonary Disease

Loading next page...
 
/lp/american-medical-association/bromocriptine-and-pleuropulmonary-disease-fVje5H2MkF

References (10)

Publisher
American Medical Association
Copyright
Copyright © 1989 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1989.00390020008002
Publisher site
See Article on Publisher Site

Abstract

Abstract Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically since 1969.1 This drug has been effective in the management of patients with hyperprolactinemia with or without a demonstrable prolactin-secreting adenoma, growth hormone-secreting pituitary adenomas, postpartum lactation, and Parkinson's disease.2 The drug also has been safely used in the management of pregnant women harboring prolactin-secreting pituitary tumors.3 In addition, the drug has been tried in some patients with luteal-phase insufficiency, idiopathic edema, premenstrual tension syndrome, and hepatic encephalopathy, although the data supporting the use of the drug in these latter conditions either are incomplete or require substantiation.1 During the 20 years of clinical experience, bromocriptine has been found to be remarkably free of major side effects.4 Patients commonly develop nausea, occasionally with abdominal cramps and vomiting, and postural hypotension at the time therapy is initiated. These side effects can References 1. Vance ML, Evans WS, Thorner MO: Bromocriptine . Ann Intern Med 1984;100:78-91.Crossref 2. Jordan RM, Kohler PO: Recent advances in diagnosis and treatment of pituitary tumors . Adv Intern Med 1987;32:299-324. 3. Melmed S, Braunstein GD, Chang J, et al: Prolactin and growth hormone-secreting pituitary tumors . Ann Intern Med 1986;105:238-253.Crossref 4. Weil C: The safety of bromocriptine in hyperprolactinemic female infertility: A literature review . Curr Med Res Opin 1986;10:172-195.Crossref 5. McElvaney NG, Wilcox PG, Churg AM, et al: Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease . Arch Intern Med 1988;148:2231-2236.Crossref 6. Wiggins J, Skinner C: Bromocriptine induced pleuropulmonary fibrosis . Thorax 1986;41:328-330.Crossref 7. Rinne UK: Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease . Lancet 1981;1:44.Crossref 8. Taal BG, Spierings EL, Hilvering C: Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine . Thorax 1983;38:396-398.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Feb 1, 1989

There are no references for this article.